Supporters are gearing up for the 7th Annual PFIC Awareness Day on Oct. 5, with advocates behind the yearly event focused on improving public awareness,…
News
FATTY LIVER DISEASE
NewsHigh blood pressure may pose greatest risk of death in MASLD
High blood pressure is a leading cardiometabolic risk factor — a condition linked to problems such as heart disease, stroke, and diabetes — associated with…
BILIARY ATRESIA
News7 genes identified as potential biliary atresia treatment targets
Researchers identified seven genes that may contribute to biliary atresia, a discovery that could provide opportunities to develop treatments or biological markers for the…
HEPATITIS
NewsProgram improves hepatitis C treatment access for new moms
A simple shift in where new mothers receive care is helping the fight against hepatitis C. By bringing infectious disease specialists to a mother’s…
Enrollment is complete in the Phase 2b VISTAS clinical trial, which is testing the experimental oral treatment volixibat in people with itching due to…
CHOLESTASIS
NewsNewly ID’d LSR gene mutations are likely cause of PFIC in 3 children
Newly identified mutations in the LSR gene were the likely cause of progressive familial intrahepatic cholestasis (PFIC) in three unrelated children — two of whom…
FATTY LIVER DISEASE
NewsRoche to acquire 89bio, will get pegozafermin for MASH in deal
As part of a merger deal, Roche will acquire 89bio and its treatment candidate pegozafermin — an injection therapy now being tested in two global…
ALAGILLE SYNDROME
NewsBylvay now approved in Canada to treat adults, children with Alagille
Bylvay (odevixibat), an oral medication used to treat cholestatic pruritus — severe itching that results from a buildup of bile acids used in digestion —…
The U.S. Food and Drug Administration (FDA) has given Lion TCR the green light to start Phase 1b/2 clinical trials testing LioCyx-M004, the clinical-stage…
CHOLANGITIS
NewsPBC treatment Ocaliva leaves U.S. market amid safety concerns
Intercept Pharmaceuticals has voluntarily withdrawn Ocaliva (obeticholic acid), an oral therapy used to treat certain adults with primary biliary cholangitis (PBC), from…
Recent Posts
- New PBC therapy found to reduce liver scarring after 1 year in US trial
- Severe itching in PFIC children disrupts sleep, family life: Registry analysis
- Don’t let liver disease keep you from chasing your dreams
- Kindergarten enrollment prompts reflection on our Alagille journey
- Parental obesity triples risk of early liver disease in children, new study finds